PITPβ Inhibitors
Chemical inhibitors of phosphatidylinositol transfer protein beta (PITPβ) operate through various modes of action to inhibit its function in cellular signaling pathways. Compounds like 1-Oleoyl-2-acetyl-sn-glycerol compete with endogenous diacylglycerol (DAG), a natural activator of protein kinase C (PKC), which is crucial for the functional activation of PITPβ. By mimicking DAG, this analog can reduce the activation of PKC, consequently inhibiting the signaling pathways that involve PITPβ. Similarly, bisindolylmaleimide I (GF109203X) and Gö 6983, both acting as selective PKC inhibitors, decrease PKC activity and thus indirectly reduce the functional role of PITPβ in the phosphoinositide signaling cascade. Other PKC inhibitors, such as staurosporine, Ro-31-8220, calphostin C, which requires light to be activated, chelerythrine chloride, and ruboxistaurin, a selective inhibitor for PKCβ, also serve to dampen the signaling processes downstream of PITPβ, effectively reducing its participation in these pathways.
Furthermore, U73122, an inhibitor of phospholipase C (PLC), curtails the production of DAG from phosphatidylinositol 4,5-bisphosphate (PIP2), thus decreasing the demand for PITPβ's lipid transfer activity. This reduction in PLC activity can lower the turnover rate of PIP2 and consequently the functional engagement of PITPβ. D609, which inhibits phosphatidylcholine-specific phospholipase C (PC-PLC), operates on a similar principle by disrupting another arm of the lipid signaling pathways that involve PITPβ. Rottlerin, though initially recognized as a specific inhibitor of PKC delta, has been found to inhibit a range of kinases, and its broad-spectrum inhibition can lead to a decrease in the cellular requirements for PITPβ's activity. Lastly, sphingosine, a natural inhibitor of PKC, can suppress the activation of PKC and the subsequent signaling pathways that rely on the lipid transfer function of PITPβ, further contributing to the inhibition of this protein's role in cellular signaling.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
1-Oleoyl-2-acetyl-sn-glycerol (OAG) | 86390-77-4 | sc-200417 sc-200417A | 10 mg 50 mg | $119.00 $453.00 | 1 | |
This synthetic analog of diacylglycerol (DAG) can compete with endogenous DAG, a known activator of protein kinase C (PKC). Since PKC is downstream of PITPβ and is required for its functional activation, the presence of this analog can reduce PKC activation, thus inhibiting the signaling pathway involving PITPβ. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent PKC inhibitor, staurosporine can inhibit the PKC-dependent pathway. Given that PITPβ is involved in the phosphatidylinositol signaling pathway, which requires PKC activity for signal propagation, staurosporine can indirectly inhibit PITPβ by reducing the downstream signaling it participates in. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Also known as GF109203X, this compound is a selective inhibitor of PKC. By inhibiting PKC, it can reduce the signaling pathway activity downstream of PITPβ, leading to a decrease in PITPβ-mediated processes. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
This compound is a pan-PKC inhibitor that can reduce PKC activity. Because PKC is essential for the signaling pathways in which PITPβ is involved, inhibiting PKC can indirectly inhibit the functional role of PITPβ in these pathways. | ||||||
Ro 31-8220 | 138489-18-6 | sc-200619 sc-200619A | 1 mg 5 mg | $92.00 $245.00 | 17 | |
As a PKC inhibitor, Ro-31-8220 can inhibit the pathways that are activated by PITPβ, resulting in a functional inhibition of the protein's role in signaling. | ||||||
Calphostin C | 121263-19-2 | sc-3545 sc-3545A | 100 µg 1 mg | $343.00 $1642.00 | 20 | |
It is a specific inhibitor of PKC that requires light activation. Its inhibition of PKC can indirectly inhibit PITPβ by decreasing the downstream signaling processes in which PITPβ is involved. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $90.00 $317.00 | 17 | |
This alkaloid acts as a PKC inhibitor. By inhibiting PKC, chelerythrine chloride can disrupt the signaling pathways that depend on PITPβ's activity, thereby inhibiting its function. | ||||||
D609 | 83373-60-8 | sc-201403 sc-201403A | 5 mg 25 mg | $189.00 $575.00 | 7 | |
This tricyclodecan-9-yl-xanthogenate inhibits phosphatidylcholine-specific phospholipase C (PC-PLC). Since PC-PLC is part of the lipid signaling pathways involving PITPβ, its inhibition can indirectly inhibit PITPβ's role in these pathways. | ||||||
Rottlerin | 82-08-6 | sc-3550 sc-3550B sc-3550A sc-3550C sc-3550D sc-3550E | 10 mg 25 mg 50 mg 1 g 5 g 20 g | $84.00 $166.00 $302.00 $2091.00 $5212.00 $16657.00 | 51 | |
Initially thought to be a specific inhibitor of PKC delta, rottlerin has been found to inhibit a broad range of kinases. By inhibiting these kinases, it can indirectly inhibit PITPβ by reducing the demand for its lipid transfer activity in cell signaling. | ||||||
Ruboxistaurin | 169939-94-0 | sc-507364 | 25 mg | $1080.00 | ||
This is a selective inhibitor of PKCβ. Since PKCβ is involved in signaling pathways downstream of PITPβ, ruboxistaurin can indirectly inhibit the functional activity of PITPβ. | ||||||